{"name": "umeclidinium", "category": "drug", "content": "Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol) and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol. It is on the World Health Organization's List of Essential Medicines. In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions.   == References =="}